Advertisement
Singapore markets open in 6 hours 34 minutes

  • Straits Times Index

    3,272.72
    +47.55 (+1.47%)
     

  • S&P 500

    5,075.06
    +64.46 (+1.29%)
     

  • Dow

    38,530.49
    +290.51 (+0.76%)
     

  • Nasdaq

    15,724.04
    +272.73 (+1.77%)
     

  • Bitcoin USD

    66,824.61
    +233.58 (+0.35%)
     

  • CMC Crypto 200

    1,437.09
    +22.33 (+1.58%)
     

  • FTSE 100

    8,044.81
    +20.94 (+0.26%)
     

  • Gold

    2,342.00
    -4.40 (-0.19%)
     

  • Crude Oil

    83.36
    +1.46 (+1.78%)
     

  • 10-Yr Bond

    4.5900
    -0.0330 (-0.71%)
     

  • Nikkei

    37,552.16
    +113.55 (+0.30%)
     

  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     

  • FTSE Bursa Malaysia

    1,561.64
    +2.05 (+0.13%)
     

  • Jakarta Composite Index

    7,110.81
    +36.99 (+0.52%)
     

  • PSE Index

    6,506.80
    +62.72 (+0.97%)
     

Amgen profit tops Street view, boosts full-year forecast

Reuters
An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. The biopharmaceutical company reports earnings on Tuesday. REUTERS/Robert Galbraith

(Reuters) - Amgen Inc (AMGN.O) on Thursday reported higher-than-expected second quarter profit and revenue, helped by strong sales of its Enbrel rheumatoid arthritis drug and cost cutting, and the company raised its full-year forecasts.

The world's largest biotechnology company said net profit rose to $1.65 billion, or $2.15 per share, from $1.55 billion, or $2.01, a year ago.

Excluding special items, Amgen earned $2.57 per share. Analysts on average expected $2.43 per share, according to Thomson Reuters I/B/E/S.

Amgen now expects 2015 adjusted earnings of $9.55 to $9.80 per share, up from its prior view of $9.35 and $9.65. It also boosted its full-year revenue expectations to between $21.1 billion and $21.4 billion, from $20.9 billion to $21.3 billion.

(Reporting by Bill Berkrot; Editing by Chizu Nomiyama)